Stemline Therapeutics (STML) Misses Q1 EPS by 1c

Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $121.4 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)